ArticleBMJ (Clinical research ed.)2024
Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study.
Article in BMJ (Clinical research ed.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Advances in the clinical applications of sodium thiosulphate.Annals of medicine · 2026Review
- Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology.Cancers · 2026Review
- Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus.Kidney international reports · 2026Article
- Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity: A Mechanistic Review.Kidney360 · 2026Review
- The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.Nature reviews. Nephrology · 2026Review
- Early differentiation between paroxysmal and persistent atrial fibrillation based on interpretable machine learning: a multicenter retrospective study.BioData mining · 2026Article
- Risk Prediction of Edentulism in Chinese Adults: Insights From the China Health and Retirement Longitudinal Study (CHARLS).International dental journal · 2026Article
- An online non-radiographic osteoporosis prediction calculator constructed using interpretable machine learning.BioData mining · 2026Article
- Inflammation: The Pathological Axis of Cisplatin-Induced Renal Injury.Journal of inflammation research · 2026Review
- Incidence of renal injury following chemotherapy in malignant tumor patients and analysis of associated factors.Frontiers in medicine · 2026Article
- Predicting Chronic Kidney Disease After Cisplatin Treatment Using Population-Level Data.JAMA oncology · 2025Article
- External validation and comparison of clinical prediction models for cisplatin-associated acute kidney injury: a single-centre retrospective study.Journal of pharmaceutical health care and sciences · 2025Article
- Predictive nomogram for severe acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: a multicenter retrospective study.Scientific reports · 2025Article
- Identification and Validation of a Prognostic Model Based on Tumour Necrosis Factor-Related mRNAs for Kidney Renal Clear Cell Carcinoma.Journal of cellular and molecular medicine · 2025Article
- Bavachin ameliorates cisplatin-induced nephrotoxicity by enhancing mitochondrial β-oxidation and lipid metabolism through MFN2.Molecular medicine (Cambridge, Mass.) · 2025Article
- Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury.JAMA oncology · 2025Article
- Reassessing Cisplatin Eligibility in Urothelial Carcinoma: A Retrospective Study on Dose Reduction Strategies.Cureus · 2025Article
- Effect of mannitol on cisplatin-associated acute kidney injury: a target trial emulation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- A machine learning-based model for predicting paroxysmal and persistent atrial fibrillation based on EHR.BMC medical informatics and decision making · 2025Observational
- Mitochondrial dysfunction and metabolic reprogramming in acute kidney injury: mechanisms, therapeutic advances, and clinical challenges.Frontiers in physiology · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
26 authors at 8 institutions in 1 country.
Funding
Abstract
objectiveTo develop and externally validate a prediction model for severe cisplatin associated acute kidney injury (CP-AKI).
designMulticenter cohort study.
settingSix geographically diverse major academic cancer centers across the US.
participantsAdults (≥18 years) receiving their first dose of intravenous cisplatin, 2006-22.
main outcome measuresThe primary outcome was CP-AKI, defined as a twofold or greater increase in serum creatinine or kidney replacement therapy within 14 days of a first dose of intravenous cisplatin. Independent predictors of CP-AKI were identified using a multivariable logistic regression model, which was developed in a derivation cohort and tested in an external validation cohort. For the primary model, continuous variables were examined using restricted cubic splines. A simple risk model was also generated by converting the odds ratios from the primary model into risk points. Finally, a multivariable Cox model was used to examine the association between severity of CP-AKI and 90 day survival.
resultsA total of 24 717 adults were included, with 11 766 in the derivation cohort (median age 59 (interquartile range (IQR) 50-67)) and 12 951 in the validation cohort (median age 60 (IQR 50-67)). The incidence of CP-AKI was 5.2% (608/11 766) in the derivation cohort and 3.3% (421/12 951) in the validation cohort. Each of the following factors were independently associated with CP-AKI in the derivation cohort: age, hypertension, diabetes mellitus, serum creatinine level, hemoglobin level, white blood cell count, platelet count, serum albumin level, serum magnesium level, and cisplatin dose. A simple risk score consisting of nine covariates was shown to predict a higher risk of CP-AKI in a monotonic fashion in both the derivation cohort and the validation cohort. Compared with patients in the lowest risk category, those in the highest risk category showed a 24.00-fold (95% confidence interval (CI) 13.49-fold to 42.78-fold) higher odds of CP-AKI in the derivation cohort and a 17.87-fold (10.56-fold to 29.60-fold) higher odds in the validation cohort. The primary model had a C statistic of 0.75 and showed better discrimination for CP-AKI than previously published models, the C statistics for which ranged from 0.60 to 0.68 (DeLong P<0.001 for each comparison). Greater severity of CP-AKI was monotonically associated with shorter 90 day survival (adjusted hazard ratio 4.63 (95% CI 3.56 to 6.02) for stage 3 CP-AKI versus no CP-AKI).
conclusionThis study found that a simple risk score based on readily available variables from patients receiving intravenous cisplatin could predict the risk of severe CP-AKI, the occurrence of which is strongly associated with death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.